Amer Bio Medica Performance
| ABMCDelisted Stock | USD 0.01 0 38.00% |
The firm shows a Beta (market volatility) of -5.54, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Amer Bio are expected to decrease by larger amounts. On the other hand, during market turmoil, Amer Bio is expected to outperform it. Amer Bio Medica right now shows a risk of 0.0%. Please confirm Amer Bio Medica standard deviation, kurtosis, market facilitation index, as well as the relationship between the jensen alpha and rate of daily change , to decide if Amer Bio Medica will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Amer Bio Medica has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound primary indicators, Amer Bio is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 98 K | |
| Free Cash Flow | -673 K |
Amer |
Amer Bio Relative Risk vs. Return Landscape
If you would invest 1.38 in Amer Bio Medica on August 28, 2024 and sell it today you would earn a total of 0.00 from holding Amer Bio Medica or generate 0.0% return on investment over 90 days. Amer Bio Medica is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Amer, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Amer Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Amer Bio's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Amer Bio Medica, and traders can use it to determine the average amount a Amer Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ABMC |
Based on monthly moving average Amer Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Amer Bio by adding Amer Bio to a well-diversified portfolio.
Amer Bio Fundamentals Growth
Amer Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Amer Bio, and Amer Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Amer Pink Sheet performance.
| Return On Asset | -0.42 | ||||
| Profit Margin | (1.13) % | ||||
| Operating Margin | (0.93) % | ||||
| Current Valuation | 2.09 M | ||||
| Shares Outstanding | 48.1 M | ||||
| Price To Earning | (6.72) X | ||||
| Price To Sales | 0.38 X | ||||
| Revenue | 2.22 M | ||||
| EBITDA | (199 K) | ||||
| Cash And Equivalents | 2 K | ||||
| Total Debt | 1.53 M | ||||
| Debt To Equity | 0.85 % | ||||
| Book Value Per Share | (0.04) X | ||||
| Cash Flow From Operations | (673 K) | ||||
| Earnings Per Share | (0.01) X | ||||
| Total Asset | 1.88 M | ||||
| Retained Earnings | (21.24 M) | ||||
| Current Asset | 2.56 M | ||||
| Current Liabilities | 1.62 M | ||||
About Amer Bio Performance
By analyzing Amer Bio's fundamental ratios, stakeholders can gain valuable insights into Amer Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Amer Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Amer Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
American Bio Medica Corporation engages in manufacture and sale of lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. American Bio Medica Corporation was incorporated in 1986 and is based in Kinderhook, New York. Amer Bio operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 32 people.Things to note about Amer Bio Medica performance evaluation
Checking the ongoing alerts about Amer Bio for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Amer Bio Medica help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Amer Bio Medica is not yet fully synchronised with the market data | |
| Amer Bio Medica has some characteristics of a very speculative penny stock | |
| Amer Bio Medica has a very high chance of going through financial distress in the upcoming years | |
| Amer Bio Medica currently holds 1.53 M in liabilities with Debt to Equity (D/E) ratio of 0.85, which is about average as compared to similar companies. Amer Bio Medica has a current ratio of 0.25, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Amer Bio until it has trouble settling it off, either with new capital or with free cash flow. So, Amer Bio's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Amer Bio Medica sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Amer to invest in growth at high rates of return. When we think about Amer Bio's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 2.22 M. Net Loss for the year was (463 K) with profit before overhead, payroll, taxes, and interest of 548 K. | |
| Amer Bio Medica currently holds about 2 K in cash with (673 K) of positive cash flow from operations. | |
| Roughly 31.0% of Amer Bio shares are held by company insiders |
- Analyzing Amer Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Amer Bio's stock is overvalued or undervalued compared to its peers.
- Examining Amer Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Amer Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Amer Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Amer Bio's pink sheet. These opinions can provide insight into Amer Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Amer Pink Sheet
If you are still planning to invest in Amer Bio Medica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Amer Bio's history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |